UK Markets closed

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.25000.0000 (0.00%)
At close: 03:58PM EST
Full screen
Loading interactive chart…
  • Business Wire

    Silence Therapeutics Reports Third Quarter 2022 Results

    LONDON, November 10, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, 2022 and reviewed recent business highlights.

  • Business Wire

    Silence Therapeutics to Present at Jefferies London Healthcare Conference

    LONDON, November 09, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present a business overview at the Jefferies London Healthcare Conference on Wednesday, November 16th at 8:00 a.m. GMT.

  • Business Wire

    Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

    LONDON, November 05, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today presented data from an analysis of its APOLLO phase 1 single dose study of SLN360, an investigational short interfering ribonucleic acid ("siRNA"), in healthy adults with high lipoprotein(a) ("Lp(a)"), a key genetic risk factor for heart diseas